UT MD Anderson opens new Colorectal Center to provide specialized care in healing environment
Â鶹ӳ» MD Anderson Cancer Center  announced the opening of its new Colorectal Center, located on the second floor of UT MD Anderson’s Duncan Building at 1155 Pressler Street. The institution hosted an event to celebrate the opening on March 18.
The new Colorectal Center reflects UT MD Anderson’s continued commitment to delivering specialized, patient-centered...
ASCO: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer
Approximately 8 to 12% of patients with colorectal cancer have BRAF mutations
Treatment with the triplet combination of drugs – encorafenib,...
Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer
ABSTRACT: 16
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the Phase III BREAKWATER trial led by researchers at Â鶹ӳ» MD Anderson Cancer Center.
The findings, presented today at the American Society of Clinical Oncology...
Combining targeted therapy and immunotherapy improves overall survival in patients with anaplastic thyroid cancer
Researchers from Â鶹ӳ» MD Anderson Cancer Center demonstrated that anti-PD-L1 immunotherapy in combination with mutation-directed...